Plain-English translation of NCT06740890 on ClinicalTrials.gov โ ยท Source last updated ยท Translation generated ยท How we translate trials
Phase 4 โ The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
This trial is testing whether olanzapine-samidorphan, a combination antipsychotic medication, works better at preventing weight gain when paired with aerobic exercise. Researchers want to see if people who exercise regularly while taking this medication gain less weight than people taking the medication alone. The study will follow participants for 8 weeks and carefully measure weight, metabolism, and how well the medication controls psychiatric symptoms.
Antipsychotic medications can cause significant weight gain, which puts patients at risk for diabetes, heart disease, and other health problems. This trial is trying to find out whether pairing the medication with exercise can reduce this unwanted side effect and improve overall health outcomes.
You likely qualify ifโฆ
You likely don't qualify ifโฆ
You will visit the research clinic several times over 8 weeks. At the start, you'll have medical tests and psychiatric evaluations to make sure the study is safe for you. You'll then take the medication for 8 weeks while also completing 2โ4 days per week of aerobic exercise (like walking, cycling, or jogging) for the first 4 weeks. The research team will measure your weight, blood sugar, cholesterol, and psychiatric symptoms at the beginning, after 4 weeks, and again at 8 weeks to see how the combination of exercise and medication affects your health.
AI-generated summary from trial data ยท Aug 10, 2026 ยท Not medical advice
United States
Phase
Post-approval monitoring
Sponsor
New York State Psychiatric Institute
Enrollment target
~30 participants
Started
June 2025
Primary completion
April 2027
Age range
18 Years โ 65 Years
Last updated on clinicaltrials.gov in July 2026.
Reach out to the team running this trial. Response times vary โ some teams are faster than others.
Central contact
Megan Mayer, BA
New York State Psychiatric Institute
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first โ no email needed to get started.